Emerald Health Pharmaceuticals is raising funds independently through Reg D 506(b) crowdfunding. It is a biotechnology company developing a new class of medicines to treat diseases with unmet needs, including CNS, and autoimmune diseases. The company is working on two families of patented chemical entities, derived from synthetic cannabidiol and cannabigerol, to treat targeted diseases. James DeMesa founded Emerald Health Pharmaceuticals in 2017. The current crowdfunding campaign has a minimum target of $100,000 and a maximum target of $300,000. The campaign proceeds will be used for clinical trials and development of the drugs.
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
Edge
$25 /month billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data